| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
4E2RCat suppresses cap-dependent translation by interfering with the interaction between the major scaffolding protein eIF4G and the cap-binding protein eIF4E. It dramatically lowers the amount of infected cells and intracellular and extracellular infectious viral titers caused by the human coronavirus 229E (HCoV-229E). Cap-dependent translation is inhibited by 4E2RCat in a dose-dependent manner. Cap-dependent FF translation is inhibited by 4E2RCat, whereas EMCV IRES-driven Ren translation is unaffected. Coronavirus replication is inhibited by 4E2RCat in a time- and dose-dependent manner [1].
|
|---|---|
| ln Vivo |
The body's inhibition of protein synthesis by 4E2RCat does not stem from a rise in cell death [1].
|
| References | |
| Additional Infomation |
4E2RCat is an organic molecular entity.
|
| Molecular Formula |
C22H14CLNO4S2
|
|---|---|
| Molecular Weight |
455.93
|
| Exact Mass |
455.005
|
| CAS # |
432499-63-3
|
| PubChem CID |
2287238
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
659.0±65.0 °C at 760 mmHg
|
| Flash Point |
352.3±34.3 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.760
|
| LogP |
5.09
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
724
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)CN2C(=O)/C(=C\C3=CC=C(O3)C4=CC(=C(C=C4)Cl)C(=O)O)/SC2=S
|
| InChi Key |
WOBPZFKXPCYOLU-YBFXNURJSA-N
|
| InChi Code |
InChI=1S/C22H14ClNO4S2/c23-17-8-6-14(10-16(17)21(26)27)18-9-7-15(28-18)11-19-20(25)24(22(29)30-19)12-13-4-2-1-3-5-13/h1-11H,12H2,(H,26,27)/b19-11+
|
| Chemical Name |
5-[5-[(E)-(3-Benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]-2-chlorobenzoic acid
|
| Synonyms |
4E2R Cat 4E2RCat4E2R-Cat
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~23.33 mg/mL (~51.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.33 mg/mL (5.11 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 23.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1933 mL | 10.9666 mL | 21.9332 mL | |
| 5 mM | 0.4387 mL | 2.1933 mL | 4.3866 mL | |
| 10 mM | 0.2193 mL | 1.0967 mL | 2.1933 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
